跳至主要内容
临床试验/NL-OMON23365
NL-OMON23365已完成不适用

The effect of galacto-oligosaccharides in constipated adults

FrieslandCampina0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
132

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Substantial:
  • Males and females
  • Age = 18 years
  • BMI =18,5 and = 28,0 kg m2.
  • Healthy as assessed by the NIZO health questionnaire
  • Self-reported constipation according to the Rome IV criteria with the following criteria (for the last 3 months):
  • oFewer than three bowel movements per week.
  • oAnd one or more of the criteria below:
  • ?straining during at least 25% of all defecations
  • ?lumpy or hard stools (Bristol Stool Form Scale 1-2) in at least 25% of defecations,
  • ?sensation of incomplete evacuation for at least 25% of defecations,
  • ?sensation of anorectal obstruction/blockage for at least 25% of defecations,
  • ?manual manoeuvres to facilitate at least 25% of defaecaltion (e.g., digital evacuation, support of the pelvic floor)
  • Procedural:
  • Ability to follow Dutch verbal and written instructions
  • Availability of internet connection
  • Signed informed consent
  • Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned.
  • Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data for at least 15 years.
  • Willing to comply with study procedures, including collection of stool samples and alcohol restriction of maximum 2 consumptions per day
  • Willing to abstain from non-prescription laxatives (starting at least 2 weeks before the start of the baseline period)
  • Willing to abstain from drugs use during the study

排除标准

  • Substantial:
  • Major abdominal surgery interfering with GI function
  • Major co-morbidities, such as diagnosed inflammatory bowel disease, diagnosed celiac disease, diagnosed diverticulitis, a history of gastrointestinal tumors and other unforeseen co-morbidities, that may have an impact on the study results (as decided by the medical investigator).
  • Use of medication that may affect the results of the investigational product, such as physician prescribed laxatives, and medication that influences the motility of the GI tract.
  • Use of antibiotics 90 days before the start of the study
  • Use of strict diets (vegan diet, gluten free diet, or crash-diet with use of meal replacers)
  • Self-reported lactose-intolerance
  • Self-reported cow’s milk protein allergy
  • Diagnosed diabetes
  • Pregnant and lactating women
  • Expected change in lifestyle within 14 days before and during the trial period (i.e. diet, physical activity, smoking, alcohol consumption and medication use)
  • History of side effect with the use of prebiotic supplements
  • Use of alcoholic beverages for men > 28 units/week and >4/day; for women: >21 units/week and >3/day
  • Procedural:
  • Not having a general practitioner, not allowing disclosure of participation to the general practitioner or not allow to inform the general practitioner about abnormal results.
  • Participation in any clinical trial including blood sampling and/or administration of substances starting 1 month prior to study start and during the entire study.
  • Personnel of NIZO or FrieslandCampina, their partner and their first and second degree relatives.

研究者

发起方
FrieslandCampina

相似试验